person
Mario H.
- Country
- Croatia
- Department
- Neurology Department
Research Overview
assignment
21
Clinical Trials ·
- Comparative Efficacy and Safety Study of CYB704 and Ocrelizumab in Relapsing Multiple Sclerosis Patients
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Phase 3 Randomized Double-Blind Study of Orelabrutinib for Primary Progressive Multiple Sclerosis in Patients With PPMS
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
278
Sites with multiple studies
Has run more than one trial at 278 of 491 partner sites.
Specializations
Multiple Sclerosis Research Focus
The investigator specializes in clinical research focusing on multiple sclerosis treatment approaches, with particular emphasis on various therapeutic modalities for both relapsing and progressive forms of the disease.
- Relapsing Multiple Sclerosis (RMS)
- Primary Progressive Multiple Sclerosis (PPMS)
- Pediatric Multiple Sclerosis
Therapeutic Innovations
Actively involved in evaluating novel therapeutic agents for multiple sclerosis, including:
- B-cell targeting therapies
- Bruton's Tyrosine Kinase inhibitors
- Monoclonal antibody treatments
Clinical Assessment Areas
Expertise in evaluating treatment outcomes through:
- Long-term safety assessments
- Disease progression monitoring
- Comparative treatment efficacy
- Neurological imaging studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.